Eli Casdin

Near­ly a year af­ter his SPAC com­bines with EQRx, Eli Cas­din re­signs from board

About 11 months af­ter his in­vest­ment firm’s blank check com­pa­ny helped boost EQRx’s cash cof­fers by about $1.3 bil­lion, Eli Cas­din is out from the biotech’s board.

The day be­fore Thanks­giv­ing, he told EQRx’s board that he would re­sign at the end of that day, ac­cord­ing to an SEC fil­ing. The de­ci­sion “was not due to any dis­agree­ment with EQRx” re­lat­ing to the com­pa­ny’s “op­er­a­tions, poli­cies or prac­tices,” as the biotech out­lined in the pa­per­work with the agency.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.